Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
On July 27, 2026, District Judge Gail A Weilheimer appointed Faruqi & Faruqi, LLP, as sole lead counsel in In re Inovio Pharmaceuticals, Inc. Securities Litigation, Docket No. 2:26-cv-00803 (E.D. Pa. Feb 06, 2026)
The Inovio Pharmaceuticals, Inc. complaint filed in this class action alleges that throughout the Class Period, the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) manufacturing for Inovio’s CELLECTRA device was deficient; (2) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA’s eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107’s overall regulatory and commercial prospects were overstated; and (5) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
For further inquiries regarding this matter, please contact James M. Wilson, Jr. at jwilson@faruqilaw.com or (212) 983-9330.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
